Nigerian Pharmaceutical companies are beginning to fill the gaps created by the exit of the likes of GlaxoSmithKline (GSK) and Sanofi that changed its model, which has led to high pricing of essential drugs and medical care.
But they need the federal government to subsidise active pharmaceutical ingredients used for drug production.
Facebook Comments Box
